HuaXiPharm investment, marketing by Hongwan Mednet

☆     Dasatinib (Dasatinib, English trade name: Sprycel,)

☆     Imatinib mesylate (Imatinib, English trade name: Glivec, )

☆     Gefitinib (Gefitinib, English trade name: Iressa, )

☆     Erlotinib (Erlotinib, English trade name: Tarceva,  

☆     Letrozole (Letrozol, the English brand name: Femara, )

Anastrozole (Anastrozole, English trade name: Arimidex ®, )
  According to the World Health Organization, cancer is a major cause of death worldwide. In 2004 7.4 million people died from cancer (about 13% of all deaths). Leading cancers that causes death every year are:

 Lung cancer (1.3 million deaths)
 Atomach cancer (803 000 deaths)
 Colorectal cancer (639 000 deaths)
 Liver cancer (610,000 deaths)
 Breast cancer (519 000 deaths).
  More than 70% of cancer deaths occur in low and middle income countries. Deaths from cancer worldwide are predicted to increase. It’s estimated 12 million people died of cancer in 2030.
  Chinese Ministry of Health statistics show that: the total number of China's new cancer patients each year is about 2.127 million people, of which about 1.06 million had malignant tumor. At same time, there are about 2.685 million cancer patients totally, in which about 1.485 million had malignant tumor.

  According to IMS statistics, since 2007 oncology drugs sales is more than the lipid-lowering drug sales, it has been a leader in the global pharmaceutical market. It reached sales volume of $ 52.372 billion in 2009. In the Chinese hospital drug market, sales volume of anticancer drugs has been growing steadily in recent years.   CAGR of it reached 24.53% between 2003 and 2005. In 2006 effected by the Anti-purchase and sale of commercial bribery and other pharmaceutical policy environment, anticancer drugs market growth was slowed down, which is an increase of 11.10%. 2007-2009 sales volume continued to grow rapidly, in 2009 it has broken through the ¥ 40 billion, reached ¥40.5 billion, with an increase of 28.57%.